Legend Biotech announced preliminary net trade sales of approximately $657 million for CARVYKTI during the quarter ended June 30, 2026. These sales figures are based on information provided by Janssen under their collaboration agreement. Legend Biotech is a biotechnology company focused on developing and commercializing cell therapies.
